These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27136911)

  • 1. Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men.
    Hu L; Jin Y; Li YG; Borel A
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):305-14. PubMed ID: 27136911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility and developmental toxicity assessment in rats and rabbits with LY500307, a selective estrogen receptor beta (ERβ) agonist.
    Hilbish KG; Breslin WJ; Johnson JT; Sloter ED
    Birth Defects Res B Dev Reprod Toxicol; 2013 Oct; 98(5):400-15. PubMed ID: 24323950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
    Zhao L; Huang S; Mei S; Yang Z; Xu L; Zhou N; Yang Q; Shen Q; Wang W; Le X; Lau WB; Lau B; Wang X; Yi T; Zhao X; Wei Y; Warner M; Gustafsson JÅ; Zhou S
    Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3673-E3681. PubMed ID: 29592953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
    Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy.
    Roehrborn CG; Spann ME; Myers SL; Serviss CR; Hu L; Jin Y
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):43-8. PubMed ID: 25348255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
    Quartino A; Huledal G; Sparve E; Lüttgen M; Bueters T; Karlsson P; Olsson T; Paraskos J; Maltby J; Claeson-Bohnstedt K; Lee CM; Alexander R; Fälting J; Paulsson B
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):396-405. PubMed ID: 27129013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.
    Bi Y; Perry PJ; Ellerby M; Murry DJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):259-268. PubMed ID: 29436172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.
    Xu H; Li J; Webber L; Kakkar R; Chen Y; Al-Huniti N
    J Clin Pharmacol; 2016 Aug; 56(8):999-1008. PubMed ID: 26626581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects.
    Shen J; Xiao J; Pickthorn K; Huang S; Bell G; Vick A; Chen P
    J Clin Pharmacol; 2014 Oct; 54(10):1125-33. PubMed ID: 24752908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
    Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
    Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
    He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women.
    Krzyzanski W; Milad MA; Jobe AH; Peppard T; Bies RR; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2021 Jun; 48(3):411-438. PubMed ID: 33954911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
    Conlan MG; de Vries EFJ; Glaudemans A; Wang Y; Troy S
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):675-689. PubMed ID: 32661909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Susceptibilities of Human Melanoma Cell Lines to G2/M Blockage and Cell Death Activation in Response to the Estrogen Receptor β agonist LY500307.
    Pontecorvi G; Bellenghi M; Tait S; Tirelli V; Matarrese P; Mattia G; Carè A; Puglisi R
    J Cancer; 2022; 13(5):1573-1587. PubMed ID: 35371312
    [No Abstract]   [Full Text] [Related]  

  • 15. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
    Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
    Li CC; Vermeersch S; Denney WS; Kennedy WP; Palcza J; Gipson A; Han TH; Blanchard R; De Lepeleire I; Depré M; Murphy MG; Van Dyck K; de Hoon JN
    Br J Clin Pharmacol; 2015 May; 79(5):831-7. PubMed ID: 25377933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.